Soficitinib Shows Positive Results in Late-Stage Atopic Dermatitis Trial

InnoCare Pharma has announced that its novel oral TYK2 inhibitor, soficitinib, successfully met its primary and key secondary endpoints in a Phase 3 study for moderate to severe atopic dermatitis. The trial demonstrated clinically meaningful improvements in disease severity and pruritus compared to placebo, alongside a favorable safety profile. These findings suggest soficitinib could become a valuable new treatment option for inflammatory skin conditions.